PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Phase 2 Terminated 513 enrolled Sun Pharma Advanced Research Company Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for subjects who have completed week 40 of Part 1

Timeline

Start: 2019-02-18
Primary completion: 2024-04-08
Completion: 2024-06-06

Outcome

Missed primary endpoint

Stopped: “Terminated based on study outcomes”

release “Part I of the PROSEEK study • Both low dose and high dose Vodobatinib arms did not meet the pre -specified primary endpoint” sparc.life ↗

Publications

Joshi D, Kulkarni M, Parekh P, Shah S, Greig NH, Acharya S. Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents. Nutr Neurosci. 2025 Dec;28(12):1532-1563. doi: 10.1080/1028415X.2025.2531356. Epub 2025 Jul 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vodobatinib	Small molecule	—	Oral